MUSTANG BIO, INC. (MBIO) - Dilution Analysis

10-Q filing | 0.8M shares outstanding

10-K filing | 0.8M shares outstanding

10-Q filing | 0.8M shares outstanding

10-Q filing | 0.8M shares outstanding

10-Q filing | 0.8M shares outstanding

POS AM filing: This prospectus relates to the offer and sale of up to 6,697,889 shares of common stock underlying certain outstanding pre-funded warrants, series C-1 common warrants, series C-2 common warrants and placement agent warrants previously issued by Mustang Bio in a public offering that closed on February 10, 2025.

10-K filing | 0.8M shares outstanding

8-K filing: Mustang Bio, Inc. closed a public offering of 495,000 shares of common stock and pre-funded warrants to purchase 2,162,807 shares, along with warrants to purchase 2,657,807 shares, for net proceeds of approximately $6.9 million, and also effected a 1-for-50 reverse stock split on January 15, 2025.

S-1/A filing: This is an S-1/A filing for offering up to 2,203,856 shares of common stock and accompanying warrants, or pre-funded warrants, for working capital and general corporate purposes.

S-3 filing: This prospectus relates to the resale by the selling stockholders of shares of our common stock issuable upon the exercise of outstanding warrants.

10-Q filing | 0.8M shares outstanding

8-K filing: Mustang Bio, Inc. closed a transaction on October 25, 2024, involving the exercise of existing warrants and the issuance of new warrants, resulting in gross proceeds of approximately $4 million for working capital and general corporate purposes. ($4.0M proceeds)

10-Q filing | 34.1M shares outstanding

S-1 filing: This prospectus relates to the resale by the selling stockholders of up to 6,497,800 shares of our common stock, par value $0.0001 per share, issuable upon the exercise of certain warrants held by the Selling Stockholders.

8-K filing: Mustang Bio, Inc. completed a registered direct offering and a concurrent private placement on June 21, 2024, selling shares of common stock and warrants to an institutional investor, raising approximately $2.5 million in gross proceeds.

S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, warrants, and debt securities, with a total offering amount of $40 million, but is currently only eligible to sell $5.6 million of securities.

10-Q filing | 9.5M shares outstanding

8-K filing: Mustang Bio, Inc. closed a public offering on May 2, 2024, selling 1,160,000 shares of common stock and pre-funded warrants to purchase up to 15,717,638 shares, along with warrants to purchase up to an aggregate of 50,632,914 additional shares of common stock for gross proceeds of approximately $3.3 million before expenses. They also issued placement agent warrants to purchase 1,012,658 shares of common stock. ($3.3M proceeds)

S-1/A filing: This S-1/A filing relates to the resale of up to 2,743,530 shares of common stock issuable upon the exercise of certain warrants held by selling stockholders.

S-1/A filing: Mustang Bio, Inc. is offering up to 15,625,000 shares of common stock, together with warrants, and pre-funded warrants to purchase shares of common stock.

S-1/A filing: The company is filing an S-1/A to register the offering of common stock, Series A-1, A-2, and A-3 warrants, pre-funded warrants, and placement agent warrants.

S-1/A filing: This S-1/A filing from 2024-04-02 discusses the issuance of common stock, restricted stock, restricted stock units, or options to employees, officers, consultants, or directors of the company, securities upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agent, and securities issued pursuant to acquisitions or strategic transactions.

S-1 filing: The company is offering shares of common stock, warrants to purchase common stock, and pre-funded warrants to purchase common stock.

10-K filing | 8.6M shares outstanding

S-1 filing: This prospectus relates to the resale by the selling stockholders of up to 2,743,530 shares of our Common Stock, issuable upon the exercise of certain warrants held by the Selling Stockholders.

10-Q filing | 8.2M shares outstanding

8-K filing: Mustang Bio, Inc. completed a registered direct offering and concurrent private placement on October 30, 2023, issuing shares, pre-funded warrants, and unregistered warrants, raising approximately $4.4 million in gross proceeds.

10-Q filing | 0.8M shares outstanding

10-Q filing | 0.8M shares outstanding

8-K filing: Stock split 15-for-1 reverse | Outstanding: 103,432,603 → 6,895,506

10-K filing | 103.4M shares outstanding

10-Q filing | 93.6M shares outstanding

10-Q filing | 93.6M shares outstanding

10-Q filing | 94.1M shares outstanding

10-K filing | 93.6M shares outstanding

8-K filing: Mustang Bio, Inc. entered into a $75.0 million loan and security agreement with Runway Growth Finance Corp., with $30.0 million funded on the Closing Date and the remaining $45.0 million fundable upon achieving certain milestones; also issued a warrant to Runway to purchase 748,036 shares of Mustang's common stock at an exercise price of $0.8021.

10-Q filing | 70.9M shares outstanding

10-Q filing | 70.9M shares outstanding

S-3/A filing: This S-3/A filing discusses the terms of Class A Preferred Stock, including dividend payments in common stock and voting rights.

10-Q filing | 70.9M shares outstanding

S-3 filing: This is an S-3 filing for a shelf registration of common stock and preferred stock.

10-K filing | 70.9M shares outstanding

10-Q filing | 39.4M shares outstanding

S-3 filing: This is an S-3 filing for a shelf registration of common stock and preferred stock.

10-Q filing | 39.4M shares outstanding

8-K filing: Mustang Bio, Inc. entered into an underwriting agreement to sell 10,769,231 shares of common stock at $3.25 per share, with an option for the underwriters to purchase an additional 1,615,384 shares. ($35.0M proceeds)

10-Q filing | 42.1M shares outstanding

10-K filing | 42.0M shares outstanding